Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp
But Frontline NSCLC Was Biggest Opportunity
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
